Integral Diagnostics (IDX) Company Presentation summary
Event summary combining transcript, slides, and related documents.
Company Presentation summary
6 Jun, 2025Key highlights and strategic positioning
Second largest radiology practice in Australia by clinic count, with 150 sites across Australia and New Zealand.
Strong industry fundamentals: ageing population, tech advancements, and supportive regulation drive demand.
Defensive revenue profile and broad GP/specialist referral network in metro and regional areas.
Industry-leading teleradiology platform and focus on operational leverage and margin improvement.
Actively managing costs and leveraging scale in procurement, IT, and recruitment.
Merger with Capitol Health
Merger has enhanced operational and financial scale, with 362 radiologists and 2,807 employees.
Pro forma FY24 revenue of $705m and operating EBITDA of $141m.
Expected to deliver over $10m in annual pre-tax net cost synergies within the first year.
Double-digit pro forma FY25 EPS accretion anticipated for shareholders.
Strengthened platform for growth, including AI-enabled technology and expanded MRI capacity.
Merger integration and cost synergies
New organisation structure and Integration Management Office established.
Cost synergies on track, with key savings in headcount, procurement, IT, and listed company costs.
Over $10m in annual pre-tax net cost synergies identified and on track for delivery.
Increased use of teleradiology and focus on radiologist recruitment and procurement efficiencies.
IDXt teleradiology platform now employs 101 teleradiologists and is growing market share.
Latest events from Integral Diagnostics
- Revenue up 55.6%, EBITDA margin at 20.6%, and merger synergies exceeded AUD 14m.IDX
H1 202624 Feb 2026 - Strong financial growth, merger synergies, and ambitious sustainability targets set for expansion.IDX
AGM 20253 Feb 2026 - Merger forms ANZ's largest listed imaging group with $10m+ synergies and a 33% premium.IDX
M&A Announcement3 Feb 2026 - Merger to form ANZ imaging leader with 155 clinics, $651M revenue, and $10M+ synergies.IDX
M&A Announcement3 Feb 2026 - Strong revenue and EBITDA growth, with a transformative merger set to reshape the business.IDX
H2 202423 Jan 2026 - Revenue and EBITDA rose, merger and digital strategy advanced, and all resolutions passed.IDX
AGM 202417 Jan 2026 - Revenue up 9.3%, strong profit growth, and merger synergies to drive future expansion.IDX
H1 202516 Dec 2025 - Strong revenue and margin growth, with merger synergies and industry tailwinds driving outlook.IDX
H2 202523 Nov 2025